Kyverna Therapeutics, Inc. (KYTX)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

6.39 on 9 Oct 2026

2 buys0 sales at will1 planned sale

Fiscal year 2025, ended 31 Dec 2025, as filed

Net income

$161.31M

Free cash flow

$153.72M

Return on equity

-69.5%

Return on capital

-52.2%

Debt to equity

0.11

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
18 Dec 2025	SEIDENBERG BETH C Director	Bought	$1,000.00K	18.1%
18 Dec 2025	Westlake BioPartners Opportunity Fund I, L.P. 10% owner	Bought	$1,000.00K	18.1%
15 Dec 2025	Walker Karen Marie Chief Technology Officer	Sold on a plan	$292.78K	51.5%
12 Feb 2024	GILEAD SCIENCES, INC. 10% owner	Bought	$20.02M	28.3%
12 Feb 2024	Bain Capital Life Sciences Investors, LLC 10% owner	Bought	$9.90M	16.6%
12 Feb 2024	Northpond Ventures III GP, LLC Former 10% Owner	Bought	$9.90M	opened

44out of 100

Profitability 0

Financial strength 73

Growth n/a

Insiders 73

Strongest on financial strength (73), weakest on profitability (0). A score of the business, not of the price.

Last 12 months

Only here

Bought

$2.00M

2 buys, 2 buyers

Sold

$292.78K

1 sale

Planned sales

100%

under a 10b5-1 plan